These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Trial data lacking for elderly patients with breast cancer. Nelson NJ J Natl Cancer Inst; 2000 Dec; 92(24):1968-9. PubMed ID: 11121451 [No Abstract] [Full Text] [Related]
45. Checkpoint inhibitors in breast cancer: hype or promise? McArthur HL Clin Adv Hematol Oncol; 2016 Jun; 14(6):392-5. PubMed ID: 27379806 [No Abstract] [Full Text] [Related]
46. Role of Herceptin in primary breast cancer: views from North America and Europe. Leyland-Jones B; Smith I Oncology; 2001; 61 Suppl 2():83-91. PubMed ID: 11694792 [TBL] [Abstract][Full Text] [Related]
47. The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium. Abair T; O'Shaughnessy J Clin Breast Cancer; 2011 Feb; 11(1):15-9. PubMed ID: 21989832 [No Abstract] [Full Text] [Related]
48. Adjuvant chemotherapy in the elderly. Biganzoli L; Aapro M Ann Oncol; 2003; 14 Suppl 3():iii1-3. PubMed ID: 12821531 [No Abstract] [Full Text] [Related]
49. Targeted Therapies for Brain Metastases from Breast Cancer. Venur VA; Leone JP Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27649142 [TBL] [Abstract][Full Text] [Related]
50. Developments in Breast Cancer 2017-2018: New Drugs, New Drug Classes-and the Prospect of More to Come. Kaklamani VG Oncology (Williston Park); 2017 Dec; 31(12 Suppl 1):6-7. PubMed ID: 29299885 [No Abstract] [Full Text] [Related]
51. Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis. Adunlin G; Cyrus JW; Dranitsaris G Breast Cancer Res Treat; 2015 Dec; 154(3):591-608. PubMed ID: 26596731 [TBL] [Abstract][Full Text] [Related]
52. Adjuvant therapies for very young women with early stage breast cancer. Freedman RA; Partridge AH Breast; 2011 Oct; 20 Suppl 3():S146-9. PubMed ID: 22015283 [TBL] [Abstract][Full Text] [Related]
53. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm]. Dalmases A; Rojo F; Rovira A; Albanell J Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407 [No Abstract] [Full Text] [Related]
54. Targeted therapy for human epidermal growth factor receptor 2-positive breast cancer: can there be too many active drugs? Chandarlapaty S; Modi S J Clin Oncol; 2011 Aug; 29(23):3111-3. PubMed ID: 21730267 [No Abstract] [Full Text] [Related]
55. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues. Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409 [TBL] [Abstract][Full Text] [Related]
56. Optimizing taxane use in MBC in the emerging era of targeted chemotherapy. von Minckwitz G; Martin M; Wilson G; Alba E; Schmidt M; Biganzoli L; Awada A Crit Rev Oncol Hematol; 2013 Mar; 85(3):315-31. PubMed ID: 23116625 [TBL] [Abstract][Full Text] [Related]
57. Next-generation targeted agents in HER2-positive metastatic breast cancer. Perez EA Clin Adv Hematol Oncol; 2012 Jul; 10(7):465-7. PubMed ID: 22895288 [No Abstract] [Full Text] [Related]
58. Advances in the treatment of breast cancer. Moulder S; Hortobagyi GN Clin Pharmacol Ther; 2008 Jan; 83(1):26-36. PubMed ID: 18091763 [TBL] [Abstract][Full Text] [Related]
59. [BOLERO -- another remarkable step in treatment of breast cancer]. Rubovszky G; Láng I Magy Onkol; 2014 Jun; 58(2):128-32. PubMed ID: 25010761 [TBL] [Abstract][Full Text] [Related]
60. Adjuvant systemic therapy for older adults with early-stage breast cancer. Pal SK; Mortimer J Womens Health (Lond); 2009 May; 5(3):251-62. PubMed ID: 19392611 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]